Clinical trial

Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care

Name

CIC1421-19-05

Description

Several Drugs used in routine care in oncology induce rare but often severe or fatal cardiovascular or metabolic side effects. This study will investigate, evaluate, report and treat the cardiovascular side effects of anticancer drugs, through a specific cardiovascular routine checkup and follow-up taking place in several Cardio-oncology programs throughout France. The different including centers will be: Assistance Publique - Hôpitaux de Paris (APHP.6: Pitié-Salpétrière, Saint Antoine and Tenon's hospitals, Paris, France).

Trial arms

Trial start

2019-03-01

Estimated PCD

2025-03-01

Trial end

2025-03-01

Status

Recruiting

Treatment

Anti-Cancer Agents

Drugs and treatments used in cancer inducing cardiovascular and metabolic side effects

Size

5000

Primary endpoint

Number of patients having a benefit after this specific cardio-oncology check up and follow up

5 years

Eligibility criteria

Inclusion Criteria: * Suffering a cancer * Evaluated within a cardio-oncology program Exclusion Criteria: * None

Protocol

{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 5000, 'type': 'ESTIMATED'}}

Updated at

2023-04-24

1 organization

1 product

8 indications

Organization

Groupe Hospitalier Pitie-Salpetriere

Product

Anti-Cancer Agents

Indication

Cardiovascular Complication

Indication